Giving Different Treatments to Prevent Nerve Problems from Chemotherapy
NCT05642611 · RecruitingThis trial looks at how three different methods help prevent nerve problems caused by chemotherapy. Chemotherapy drugs called taxanes, like paclitaxel and docetaxel, can lead to symptoms like numbness or pain in the arms and legs. The study will use a special device to cool and compress the limbs during treatment. Researchers hope to find out which method works best in preventing these nerve issues.
Locations and contact
This trial is running at 36 locations in the United States. 33 of them are currently recruiting.
United States36 locations · 33 recruiting
- Baptist Health LexingtonLexington, KentuckyRecruiting
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, TexasRecruiting
- Bon Secours Saint Francis Medical CenterMidlothian, VirginiaRecruiting
- CaroMont Regional Medical CenterGastonia, North CarolinaRecruiting
- Cone Health Cancer CenterGreensboro, North CarolinaRecruiting
- Corewell Health Grand Rapids Hospitals - Butterworth HospitalGrand Rapids, MichiganRecruiting
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer CenterLebanon, New HampshireRecruiting
- Emory University Hospital/Winship Cancer InstituteAtlanta, GeorgiaRecruiting
- Gibbs Cancer Center-GaffneyGaffney, South CarolinaRecruiting
- Gibbs Cancer Center-PelhamGreer, South CarolinaRecruiting
- Good Samaritan Hospital - CincinnatiCincinnati, OhioRecruiting
- Henry Ford HospitalDetroit, MichiganRecruiting
- Henry Ford Macomb Hospital-Clinton TownshipClinton Township, MichiganRecruiting
- Kapiolani Medical Center for Women and ChildrenHonolulu, HawaiiRecruiting
- Margaret R Pardee Memorial HospitalHendersonville, North CarolinaRecruiting
- McLeod Regional Medical CenterFlorence, South CarolinaRecruiting
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, New YorkRecruiting
- Regional Cancer Center at Johnson City Medical CenterJohnson City, TennesseeRecruiting
- Rhode Island HospitalProvidence, Rhode IslandRecruiting
- SMC Center for Hematology Oncology UnionUnion, South CarolinaRecruiting
- Smilow Cancer Hospital Care Center-FairfieldFairfield, ConnecticutRecruiting
- Smilow Cancer Hospital Care Center-TrumbullTrumbull, ConnecticutRecruiting
- Spartanburg Medical CenterSpartanburg, South CarolinaRecruiting
- STCC at DHR Health Institute for Research and DevelopmentEdinburg, TexasRecruiting
- The Valley Hospital - Luckow PavilionParamus, New JerseyRecruiting
- University of Alabama at Birmingham Cancer CenterBirmingham, AlabamaRecruiting
- University of Kansas Cancer CenterKansas City, KansasRecruiting
- University of Kansas Hospital-Indian Creek CampusOverland Park, KansasRecruiting
- University of Kansas Hospital-Westwood Cancer CenterWestwood, KansasRecruiting
- University of New Mexico Cancer CenterAlbuquerque, New MexicoRecruiting
- University of Washington Medical Center - MontlakeSeattle, WashingtonRecruiting
- Valley Health System Ridgewood CampusRidgewood, New JerseyRecruiting
- Yale UniversityNew Haven, ConnecticutRecruiting
- Contra Costa Regional Medical CenterMartinez, CaliforniaSuspended
- Fred Hutchinson Cancer CenterSeattle, WashingtonSuspended
- State University of New York Upstate Medical UniversitySyracuse, New YorkActive Not Recruiting
Who can join
This trial is for adults aged 18 and older who have a solid tumor cancer and are starting chemotherapy soon. Participants must be able to complete questionnaires in English or Spanish. Some people, like those with certain nerve issues or skin problems, cannot join. The trial team will confirm eligibility for everyone.
What happens during the trial
Participants will be randomly placed into one of three groups. One group will use cryocompression, which cools and applies moderate pressure to the limbs. The second group will receive continuous compression, which applies steady pressure. The third group will use low cyclic compression, which applies gentle pressure that alternates. Everyone may also provide blood samples during the study.
The trial team
The trial is run by the SWOG Cancer Research Network with support from the National Cancer Institute. The principal investigators are Melissa K Accordino from SWOG - Columbia University and Katherine Pennington, MD from NRG - University of Washington.
Important dates
The trial started on June 6, 2023, and is expected to finish by August 30, 2031. It is currently enrolling new participants.
Additional information
The trial's ID number is NCT05642611. It is a Phase 3 study, which means it is looking at how well the methods work and how safe they are. The study is not using FDA-regulated drugs or devices, and it hopes to enroll around 777 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →